People · Operator

Earl A. Bright II

Named in public records as an officer, director or promoter · active 2017–2020 · Other Health Care

2
Companies
3
Filings
$58.8M
Combined raised · real
Serial
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Revelle Aesthetics, Inc.Other Health CareSeries C$50.0M$1.1B2020
ExploraMed V, L.L.C.Other Health CareSeries A$8.8M$176.7M2017
Operator network

Earl A. Bright II at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Nina W Richardson · 2 companies · 1 sharedNina W RichardsonCaroline Van Hove · 1 companies · 1 sharedCaroline Van HoveCaroline Van Hove Eberle · 1 companies · 1 sharedCaroline Van Hove…David W. Amerson · 1 companies · 1 sharedDavid W. AmersonKaren W. Long · 1 companies · 1 sharedKaren W. LongPhilippe W. Schaison · 1 companies · 1 sharedPhilippe W. Schai…Robert W. Croce · 7 companies · 2 sharedRobert W. CroceJoshua A. Makower · 2 companies · 2 sharedJoshua A. MakowerRobert A. Anderson · 2 companies · 1 sharedRobert A. AndersonIvy A. Ross · 1 companies · 1 sharedIvy A. RossNina A. Richardson · 1 companies · 1 sharedNina A. RichardsonRevelle Aesthetics, Inc. · $50.0M raisedRevelle Aesthetics, I…ExploraMed V, L.L.C. · $8.8M raisedExploraMed V, L.L.C.Earl A. Bright IIEI
Earl A. Bright II Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Earl A. Bright II on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Robert W. Croce27
Joshua A. Makower22
Robert A. Anderson12
Nina W Richardson12
David W. Amerson11
Caroline Van Hove Eberle11
Ivy A. Ross11
Nina A. Richardson11
Philippe W. Schaison11
Caroline Van Hove11
Karen W. Long11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.